{"id":"NCT00911534","sponsor":"Eisai Inc.","briefTitle":"Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)","officialTitle":"A Multicenter Randomized Double-Blind Study to Compare the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-01","primaryCompletion":"2009-07","completion":"2009-10","firstPosted":"2009-06-02","resultsPosted":"2016-02-02","lastUpdate":"2016-02-02"},"enrollment":305,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Symptomatic Gastroesophageal Reflux Disease (sGERD)"],"interventions":[{"type":"DRUG","name":"rabeprazole sodium","otherNames":["rabeprazole sodium extended release"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to compare the efficacy, safety and tolerability of rabeprazole extended release (ER) 50 mg with placebo in subjects with symptomatic gastroesophageal reflux disease (sGERD).","primaryOutcome":{"measure":"Mean Percentage of Diary-Recorded Heartburn-Free Days at Week 4","timeFrame":"Week 4","effectByArm":[{"arm":"Placebo","deltaMin":21.23,"sd":26.8},{"arm":"RAB ER 50mg","deltaMin":41.14,"sd":34.49}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":98,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":147},"commonTop":[]}}